Intraarterial melphalan infusion for intraocular retinoblastoma in children
Record ID 32011001353
English
Authors' objectives:
Retinoblastoma is a rapidly developing cancer that arises in the retina of the eye. In children it is the most common primary tumor of the eye. The estimated annual incidence in the United States is approximately 4 per 1 million children < 15 years of age. Primary treatment of advanced retinoblastoma involves systemic chemotherapy and a combination of focal consolidative therapies resulting in a 5-year disease-free survival rate of more than 93% in children younger than 5 years. However, systemic chemotherapy is associated with serious side effects. Novel ways of delivering chemotherapy locally to the eye while minimizing systemic exposure have been developed.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=12414
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Infusions, Intra-Arterial
- Melphalan
- Retinal Neoplasms
- Retinoblastoma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.